The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Biologic Therapies for Severe Asthma
Open accessAbstract
Patients with severe asthma are at increased risk for a decreased quality of life, fixed airway obstruction, hospitalization, and death. Biologics may be required to reduce the disease burden. This review discusses the mechanisms, efficacy, and safety of biologics for severe asthma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Factors associated with COVID-19-related death using OpenSAFELY
Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., Curtis, H. J., Mehrkar, A., Evans, D., Inglesby, P., et al. (2020) · Nature · doi:10.1038/s41586-020-2521-4 · Cited by 6,674
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
Eosinophilic Inflammation in Asthma
Bousquet, J., Chanez, P., Lacoste, J. Y., Barnéon, G., Ghavanian, N., Enander, I., Venge, P., Ahlstedt, S., Simony-Lafontaine, J., Godard, P., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010113231505 · Cited by 2,499
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322
Self-citationPavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Castro, M., Corren, J., Pavord, I. D., Maspero, J., Wenzel, S., Rabe, K. F., Busse, W. W., Ford, L., Sher, L., FitzGerald, J. M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804092 · Cited by 1,986
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,871
T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
Woodruff, P. G., Modrek, B., Choy, D. F., Jia, G., Abbas, A. R., Ellwanger, A., Arron, J. R., Koth, L. L., & Fahy, J. V. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0392oc · Cited by 1,803
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Bel, E. H., Wenzel, S. E., Thompson, P. J., Prazma, C. M., Keene, O. N., Yancey, S. W., Ortega, H. G., & Pavord, I. D. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403291 · Cited by 1,661
Type 2 inflammation in asthma — present in most, absent in many
Fahy, J. V. (2015) · Nature Reviews Immunology · doi:10.1038/nri3786 · Cited by 1,654
Bleecker, E. R., FitzGerald, J. M., Chanez, P., Papi, A., Weinstein, S. F., Barker, P., Sproule, S., Gilmartin, G., Aurivillius, M., Werkström, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31324-1 · Cited by 1,406
FitzGerald, J. M., Bleecker, E. R., Nair, P., Korn, S., Ohta, K., Lommatzsch, M., Ferguson, G. T., Busse, W. W., Barker, P., Sproule, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31322-8 · Cited by 1,397
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Nair, P., Pizzichini, M. M. M., Kjarsgaard, M., Inman, M. D., Efthimiadis, A., Pizzichini, E., Hargreave, F. E., & O'Byrne, P. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805435 · Cited by 1,356
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Rabe, K. F., Nair, P., Brusselle, G., Maspero, J. F., Castro, M., Sher, L., Zhu, H., Hamilton, J. D., Swanson, B. N., Khan, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804093 · Cited by 1,184
Self-citationCastro, M., Zangrilli, J., Wechsler, M. E., Bateman, E. D., Brusselle, G. G., Bardin, P., Murphy, K., Maspero, J. F., O'Brien, C., & Korn, S. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00042-9 · Cited by 1,182
Self-citationThe basic immunology of asthma
Hammad, H., & Lambrecht, B. N. (2021) · Cell · doi:10.1016/j.cell.2021.02.016 · Cited by 1,105
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Wechsler, M. E., Akuthota, P., Jayne, D., Khoury, P., Klion, A., Langford, C. A., Merkel, P. A., Moosig, F., Specks, U., Cid, M. C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702079 · Cited by 1,094
After asthma: redefining airways diseases
Pavord, I. D., Beasley, R., Agusti, A., Anderson, G. P., Bel, E., Brusselle, G., Cullinan, P., Custovic, A., Ducharme, F. M., Fahy, J. V., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)30879-6 · Cited by 1,073
Self-citationTezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
Menzies-Gow, A., Corren, J., Bourdin, A., Chupp, G., Israel, E., Wechsler, M. E., Brightling, C. E., Griffiths, J. M., Hellqvist, Å., Bowen, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034975 · Cited by 1,056
Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
Nair, P., Wenzel, S., Rabe, K. F., Bourdin, A., Lugogo, N. L., Kuna, P., Barker, P., Sproule, S., Ponnarambil, S., & Goldman, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703501 · Cited by 1,044
Exploring the Effects of Omalizumab in Allergic Asthma: An Analysis of Biomarkers in the EXTRA Study
Hanania, N. A., Wenzel, S., Rosén, K., Hsieh, H.-J., Mosesova, S., Choy, D. F., Lal, P., Arron, J. R., Harris, J. M., & Busse, W. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201208-1414oc · Cited by 901
Bachert, C., Mannent, L., Naclerio, R. M., Mullol, J., Ferguson, B. J., Gevaert, P., Hellings, P., Jiao, L., Wang, L., Evans, R. R., et al. (2016) · JAMA · doi:10.1001/jama.2015.19330 · Cited by 794
Fahy, J. V., Fleming, H. E., Wong, H. H., Liu, J. T., Su, J. Q., Reimann, J., Fick, R. B., & Boushey, H. A. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.6.9196082 · Cited by 713
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease
Pavord, I. D., Chanez, P., Criner, G. J., Kerstjens, H. A. M., Korn, S., Lugogo, N., Martinot, J.-B., Sagara, H., Albers, F. C., Bradford, E. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708208 · Cited by 625
Chupp, G. L., Bradford, E. S., Albers, F. C., Bratton, D. J., Wang-Jairaj, J., Nelsen, L. M., Trevor, J. L., Magnan, A., & ten Brinke, A. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30125-x · Cited by 599
Thaçi, D., Simpson, E. L., Beck, L. A., Bieber, T., Blauvelt, A., Papp, K., Soong, W., Worm, M., Szepietowski, J. C., Sofen, H., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00388-8 · Cited by 572
Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia
Laviolette, M., Gossage, D. L., Gauvreau, G., Leigh, R., Olivenstein, R., Katial, R., Busse, W. W., Wenzel, S., Wu, Y., Datta, V., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.05.020 · Cited by 511
Severe and Difficult-to-Treat Asthma in Adults
Israel, E., & Reddel, H. K. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1608969 · Cited by 474
An expert consensus framework for asthma remission as a treatment goal
Menzies-Gow, A., Bafadhel, M., Busse, W. W., Casale, T. B., Kocks, J. W. H., Pavord, I. D., Szefler, S. J., Woodruff, P. G., de Giorgio-Miller, A., Trudo, F., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.12.006 · Cited by 434
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma
Wechsler, M. E., Ruddy, M. K., Pavord, I. D., Israel, E., Rabe, K. F., Ford, L. B., Maspero, J. F., Abdulai, R. M., Hu, C.-C., Martincova, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024257 · Cited by 425
Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management
Bleecker, E. R., Menzies-Gow, A. N., Price, D. B., Bourdin, A., Sweet, S., Martin, A. L., Alacqua, M., & Tran, T. N. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201904-0903so · Cited by 380
Benralizumab for the Prevention of COPD Exacerbations
Criner, G. J., Celli, B. R., Brightling, C. E., Agusti, A., Papi, A., Singh, D., Sin, D. D., Vogelmeier, C. F., Sciurba, F. C., Bafadhel, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1905248 · Cited by 351
Diver, S., Khalfaoui, L., Emson, C., Wenzel, S. E., Menzies-Gow, A., Wechsler, M. E., Johnston, J., Molfino, N., Parnes, J. R., Megally, A., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00226-5 · Cited by 328
Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial
Kelsen, S. G., Agache, I. O., Soong, W., Israel, E., Chupp, G. L., Cheung, D. S., Theess, W., Yang, X., Staton, T. L., Choy, D. F., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.03.044 · Cited by 319
FitzGerald, J. M., Bleecker, E. R., Menzies-Gow, A., Zangrilli, J. G., Hirsch, I., Metcalfe, P., Newbold, P., & Goldman, M. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30344-2 · Cited by 318
Busse, W. W., Bleecker, E. R., FitzGerald, J. M., Ferguson, G. T., Barker, P., Sproule, S., Olsson, R. F., Martin, U. J., Goldman, M., Yañez, A., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30406-5 · Cited by 314
Khatri, S., Moore, W., Gibson, P. G., Leigh, R., Bourdin, A., Maspero, J., Barros, M., Buhl, R., Howarth, P., Albers, F. C., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.09.033 · Cited by 304
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Bacharier, L. B., Maspero, J. F., Katelaris, C. H., Fiocchi, A. G., Gagnon, R., de Mir, I., Jain, N., Sher, L. D., Mao, X., Liu, D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2106567 · Cited by 290
Casale, T. B., Luskin, A. T., Busse, W., Zeiger, R. S., Trzaskoma, B., Yang, M., Griffin, N. M., & Chipps, B. E. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2018.04.043 · Cited by 276
Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma
Kavanagh, J. E., Hearn, A. P., Dhariwal, J., d’Ancona, G., Douiri, A., Roxas, C., Fernandes, M., Green, L., Thomson, L., Nanzer, A. M., et al. (2021) · Chest · doi:10.1016/j.chest.2020.08.2083 · Cited by 263
Mepolizumab effectiveness and identification of super-responders in severe asthma
Harvey, E. S., Langton, D., Katelaris, C., Stevens, S., Farah, C. S., Gillman, A., Harrington, J., Hew, M., Kritikos, V., Radhakrishna, N., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02420-2019 · Cited by 190
Treatment options in type-2 low asthma
Hinks, T. S. C., Levine, S. J., & Brusselle, G. G. (2021) · European Respiratory Journal · doi:10.1183/13993003.00528-2020 · Cited by 187
Self-citationLong-Term Therapy Response to Anti–IL-5 Biologics in Severe Asthma—A Real-Life Evaluation
Eger, K., Kroes, J. A., ten Brinke, A., & Bel, E. H. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.10.010 · Cited by 180
Harrison, T. W., Chanez, P., Menzella, F., Canonica, G. W., Louis, R., Cosio, B. G., Lugogo, N. L., Mohan, A., Burden, A., McDermott, L., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30414-8 · Cited by 175
Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics
Porsbjerg, C. M., Sverrild, A., Lloyd, C. M., Menzies-Gow, A. N., & Bel, E. H. (2020) · European Respiratory Journal · doi:10.1183/13993003.00260-2020 · Cited by 174
Severe Adult Asthmas: Integrating Clinical Features, Biology, and Therapeutics to Improve Outcomes
Wenzel, S. E. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202009-3631ci · Cited by 166
Clinical utility of fractional exhaled nitric oxide in severe asthma management
Menzies-Gow, A. N., Mansur, A. H., & Brightling, C. E. (2020) · European Respiratory Journal · doi:10.1183/13993003.01633-2019 · Cited by 160
Advances in understanding and reducing the burden of severe asthma in children
Pijnenburg, M. W., & Fleming, L. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30399-4 · Cited by 159
Liu, S., Cao, Y., Du, T., & Zhi, Y. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.11.054 · Cited by 158
Middleton, P. G., Gade, E. J., Aguilera, C., Mackillop, L. H., Button, B., Coleman, C., Johnson, B. A., Albrechtsen, C. K., Edenborough, F. P., Comas, D. R., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01208-2019 · Cited by 149
Dupin, C., Belhadi, D., Guilleminault, L., Gamez, A. S., Berger, P., Frederic de, B. L. A. Y., Bonniaud, P., Leroyer, C., Mahay, G., Girodet, P., et al. (2020) · Clinical & Experimental Allergy · doi:10.1111/cea.13614 · Cited by 143
Risankizumab in Severe Asthma — A Phase 2a, Placebo-Controlled Trial
Brightling, C. E., Nair, P. K., Cousins, D. J., Louis, R. E., & Singh, D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030880 · Cited by 131
Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils
Brusselle, G., Germinaro, M., Weiss, S., & Zangrilli, J. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.01.011 · Cited by 127
Self-citationGupta, A., Ikeda, M., Geng, B., Azmi, J., Price, R. G., Bradford, E., Yancey, S. W., & Steinfeld, J. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.005 · Cited by 119
Frøssing, L., Silberbrandt, A. W., von Bülow, A., Backer, V., & Porsbjerg, C. M. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.09.051 · Cited by 116
Wechsler, M. E., Colice, G., Griffiths, J. M., Almqvist, G., Skärby, T., Piechowiak, T., Kaur, P. P., Bowen, K., Hellqvist, Å., Mo, M. F., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-01503-z · Cited by 93
Bernstein, J. A., Virchow, J. C., Jr., Murphy, K. R., Maspero, J. F., Jacobs, J., Adir, Y., Humbert, M. J. C., Castro, M., Marsteller, D. A., McElhattan, J., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30372-8 · Cited by 87
Self-citationTaillé, C., Chanez, P., Devouassoux, G., Didier, A. P., Pison, C. M., Garcia, G., Charriot, J., Bouée, S., Gruber, A., Pribil, C., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02345-2019 · Cited by 83
Treatment of Hypertension in Patients with Asthma
Christiansen, S. C., & Zuraw, B. L. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1800345 · Cited by 76
Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent
Krings, J. G., McGregor, M. C., Bacharier, L. B., & Castro, M. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.03.008 · Cited by 71
Biologicals in atopic disease in pregnancy: An EAACI position paper
Pfaller, B., Yepes-Núñez, J. J., Agache, I. O., Akdiş, C. A., Alsalamah, M., Bavbek, S., Bossios, A., Boyman, O., Chaker, A. M., Chan, S., et al. (2020) · Allergy · doi:10.1111/all.14282 · Cited by 69
Buhl, R., Bel, E. H., BOURDIN, A. A., Davila, I. J., Douglass, J. A., FitzGerald, J. M., Jackson, D. J., Lugogo, N. L., Matucci, A., Pavord, I. D., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.10.059 · Cited by 64
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
Castro, M., Rabe, K. F., Corren, J., Pavord, I. D., Katelaris, C. H., Tohda, Y., Zhang, B., Rice, M. S., Maroni, J. M., Rowe, P., et al. (2020) · ERJ Open Research · doi:10.1183/23120541.00204-2019 · Cited by 57
Variability in Blood Eosinophil Counts in Patients with Eosinophilic Asthma
Corren, J., Du, E. Y., Gubbi, A., & Vanlandingham, R. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.10.033 · Cited by 46
How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit
Pepper, A. N., Hanania, N. A., Humbert, M. J. C., & Casale, T. B. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.10.048 · Cited by 43
Dupilumab efficacy in adolescents with uncontrolled, moderate‐to‐severe asthma: LIBERTY ASTHMA QUEST
Maspero, J. F., FitzGerald, J. M., Pavord, I. D., Rice, M. S., Maroni, J. M., Rowe, P. J., Pirozzi, G., Amin, N., Ruddy, M. K., Graham, N. M. H., et al. (2021) · Allergy · doi:10.1111/all.14872 · Cited by 38
Making Precision Medicine Socially Precise. Take a Deep Breath
Oh, S. S., White, M. J., Gignoux, C. R., & Burchard, E. G. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201510-2045ed · Cited by 35
Samedy-Bates, L.-A., Oh, S. S., Nuckton, T. J., Elhawary, J. R., White, M. J., Elliot, T., Zeiger, A. M., Eng, C. S., Salazar, S., LeNoir, M. A., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1555 · Cited by 22
Cited by
Current Understanding of Asthma Pathogenesis and Biomarkers
Habib, N., Pasha, M. A., & Tang, D. D. (2022) · Cells · doi:10.3390/cells11172764 · Cited by 299
Biologics and airway remodeling in severe asthma
Varricchi, G., Ferri, S., Pepys, J., Poto, R., Spadaro, G., Nappi, E., Paoletti, G., Virchow, J. C., Heffler, E., & Canonica, W. G. (2022) · Allergy · doi:10.1111/all.15473 · Cited by 254
Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases
Jiménez‐Saiz, R., Iborra, S., Blanco, C., González‐Pérez, R., Nuñez‐Borque, E., Zeyneloglu, C., Babayev, H., Göksel, O., Göksel, T., Khaitov, M., et al. (2026) · Allergy · doi:10.1111/all.70512 · Cited by 2
Metadata
- Authors
- Brusselle, G. G., & Koppelman, G. H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-01-13
- Volume
- 386
- Issue
- 2
- Pages
- 157-171
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4205656076
- Cited by
- 715
- References
- 68
- FWCI
- 77.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.